Recommend Human Vaccines to your librarian for 2008. Download form here.
Email this page
Print this page
Research Paper
Immunogenicity and Reactogenicity to Haemophilus influenzae Type b (Hib) Conjugate Vaccine Among Rural Alaska Adults
Catherine M. Dentinger, Thomas W. Hennessy, Lisa R. Bulkow, Alisa L. Reasonover, Sandra Romero-Steiner, Patricia Holder, Patricia Gomez de Leon, George M. Carlone, Debra J. Parks, Alan J. Parkinson, Rosalyn J. Singleton, Orin S. Levine and Jay C. Butler
volume 2 | issue 1
january/february 2006Pages: 24 - 28
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
Background: Despite routine vaccination and declining disease rates, Haemophilus influenzae type b (Hib) invasive disease still occurs in rural Alaska. Colonization studies indicate persistent transmission of Hib among village residents, including adults. As part of a project to eliminate Hib carriage in 3 rural villages, we evaluated a cohort of Alaska adults for antibody response and reactogenicity to a single dose of Hib conjugate vaccine (HbOC). Methods: 75 previously unvaccinated, randomly-selected adults in one village received a single dose of HbOC vaccine and completed a side-effects diary. Sera and oropharyngeal specimens were collected at baseline, 2 months and 1 year. Results: No participants were colonized with Hib or reported serious side-effects. At baseline, 97% of adults had IgG anti-PRP concentrations > 0.15 µg/mL, 69% >1 µg/mL, and 28% > 5 µg/mL. Two months post-vaccination, 100% of participants had concentrations > 0.15 µg/mL, 93% >1 µg/mL, and 86% >5 µg/mL. After 1 year, 98% had IgG anti-PRP concentrations > 0.15 µg/mL, 86% > 1 µg/mL, and 67% >5 µg/mL. GMCs were 1.9, 33.3 and 8.4 µg/mL at baseline, 2 months and 1 year post-vaccine, respectively (p<0.01). Serum bactericidal activity increased from a baseline geometric mean titer of 2,205 to 8,349 two months post vaccination and declined to 1102 after one year. Conclusions: HbOC vaccine was immunogenic and well-tolerated among Alaskan adults. Nearly 90% of the adults developed an antibody level associated with protection against Hib colonization which persisted for 1 year in 67% of participants.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.